Patient info Open main menu

Mirapexin - patient leaflet, side effects, dosage

Contains active substance:

Dostupné balení:

Patient leaflet - Mirapexin

1. What MIRAPEXIN is and what it is used for

MIRAPEXIN contains the active substance pramipexole and belongs to a group of medicines known as dopamine agonists, which stimulate dopamine receptors in the brain. Stimulation of the dopamine receptors triggers nerve impulses in the brain that help to control body movements.

MIRAPEXIN is used to:

  • – treat the symptoms of primary Parkinson’s disease in adults. It can be used alone or in combination with levodopa (another medicine for Parkinson’s di­sease).

  • – treat the symptoms of moderate to severe primary Restless Legs Syndrome in adults.

2. What you need to know before you take MIRAPEXIN

Do not take MIRAPEXIN:

  • – if you are allergic to pramipexole or to any of the other ingredients of this medicine (listed in section 6).

Warnings and precautions

Talk to your doctor before taking MIRAPEXIN. Tell your doctor if you have (had) or develop any medical conditions or symptoms, especially any of the following:

  • – Kidney disease

  • – Hallucinations (seeing, hearing or feeling things that are not there). Most hallucinations are visual.

  • – Dyskinesia (e.g. abnormal, uncontrolled movements of the limbs). If you have advanced

Parkinson’s disease and are also taking levodopa, you might develop dyskinesia during the up-titration of MIRAPEXIN.

  • – Dystonia (inability of keeping your body and neck straight and upright (axial dystonia)). In particular, you may experience forward flexion of the head and neck (also called antecollis), forward bending of the lower back (also called camptocormia) or sidewards bending of the back (also called pleurothotonus or Pisa Syndrome).

  • – Sleepiness and episodes of suddenly falling asleep

  • – Psychosis (e.g. comparable with symptoms of schizophrenia)

  • – Vision impairment. You should have regular eye examinations during treatment with MIRAPEXIN.

  • – Severe heart or blood vessels disease. You will need to have your blood pressure checked

regularly, especially at the beginning of treatment. This is to avoid postural hypotension (a fall in blood pressure on standing up).

  • – Augmentation. You may experience that symptoms start earlier than usual, be more intense and involve other limbs.

Tell your doctor if you or your family/carer notices that you are developing urges or cravings to behave in ways that are unusual for you and you cannot resist the impulse, drive or temptation to carry out certain activities that could harm yourself or others. These are called impulse control disorders and can include behaviours such as addictive gambling, excessive eating or spending, an abnormally high sex drive or preoccupation with an increase in sexual thoughts or feelings. Your doctor may need to adjust or stop your dose.

Tell your doctor if you or your family/carer notices that you are developing mania (agitation, feeling elated or over-excited) or delirium (decreased awareness, confusion or loss of reality). Your doctor may need to adjust or stop your dose.

Tell your doctor if you experience symptoms such as depression, apathy, anxiety, fatigue, sweating or pain after stopping or reducing your MIRAPEXIN treatment. If the problems persist more than a few weeks, your doctor may need to adjust your treatment.

Tell your doctor if you are developing an inability of keeping your body and neck straight and upright (axial dystonia). If this happens, your doctor may want to adjust or change your medication.

Children and adolescents

MIRAPEXIN is not recommended for use in children or adolescents under 18 years.

Other medicines and MIRAPEXIN

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This includes medicines, herbal remedies, health foods or supplements that you have obtained without a prescription.

You should avoid taking MIRAPEXIN together with antipsychotic medicines.

Take care if you are taking the following medicines:

  • – cimetidine (to treat excess stomach acid and stomach ulcers)

  • – amantadine (which can be used to treat Parkinson’s di­sease)

  • – mexiletine (to treat irregular heartbeats, a condition known as ventricular arrhythmia)

  • – zidovudine (which can be used to treat the acquired immune deficiency syndrome (AIDS), a disease of the human immune system)

  • – cisplatin (to treat various types of cancers)

  • – quinine (which can be used for the prevention of painful night-time leg cramps and for the treatment of a type of malaria known as falciparum malaria (malignant malaria))

  • – procainamide (to treat irregular heart beat)

If you are taking levodopa, the dose of levodopa is recommended to be reduced when you start treatment with MIRAPEXIN.

Take care if you are using any medicines that calm you down (have a sedative effect) or if you are drinking alcohol. In these cases MIRAPEXIN may affect your ability to drive and operate machinery.

MIRAPEXIN with food, drink and alcohol

You should be cautious while drinking alcohol during treatment with MIRAPEXIN. MIRAPEXIN can be taken with or without food.

Pregnancy and breast-feeding

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine. Your doctor will then discuss with you if you should continue to take MIRAPEXIN.

The effect of MIRAPEXIN on the unborn child is not known. Therefore, do not take MIRAPEXIN if you are pregnant unless your doctor tells you to do so.

MIRAPEXIN should not be used during breast-feeding. MIRAPEXIN can reduce the production of breast milk. Also, it can pass into the breast milk and can reach your baby. If use of MIRAPEXIN is unavoidable, breast-feeding should be stopped.

Ask your doctor or pharmacist for advice before taking any medicine.

Driving and using machines

MIRAPEXIN can cause hallucinations (seeing, hearing or feeling things that are not there). If affected, do not drive or use machines.

MIRAPEXIN has been associated with sleepiness and episodes of suddenly falling asleep, particularly in patients with Parkinson’s di­sease. If you experience these side effects, you must not drive or operate machinery. You should tell your doctor if this occurs.

3. How to take MIRAPEXIN

Always take this medicine exactly as your doctor has told you. Check with your doctor if you are not sure. The doctor will advise you on the right dosing.

You can take MIRAPEXIN with or without food. Swallow the tablets with water.

Parkinson’s di­sease

The daily dose is to be taken divided into 3 equal doses.

During the first week, the usual dose is 1 tablet MIRAPEXIN 0.088 mg three times a day (equivalent to 0.264 mg daily):

1st week

Number of tablets

1 tablet MIRAPEXIN 0.088 mg three times a day

Total daily dose (mg)

0.264

This will be increased every 5–7 days as directed by your doctor until your symptoms are controlled (maintenance dose).

2nd week

3rd week

Number of tablets

  • 1 tablet MIRAPEXIN 0.18 mg three times a day OR

  • 2 tablets MIRAPEXIN 0.088 mg three times a day

  • 1 tablet MIRAPEXIN 0.35 mg three times a day OR

  • 2 tablets MIRAPEXIN 0.18 mg three times a day

Total daily dose (mg)

0.54

1.1

The usual maintenance dose is 1.1 mg per day. However, your dose may have to be increased even further. If necessary, your doctor may increase your tablet dose up to a maximum of 3.3 mg of pramipexole a day. A lower maintenance dose of three MIRAPEXIN 0.088 mg tablets a day is also possible.

Lowest maintenance dose

Highest maintenance dose

Number of tablets

1 tablet MIRAPEXIN 0.088 mg three times a day

1 tablet MIRAPEXIN 0.7 mg and 1 tablet MIRAPEXIN 0.35 mg three times a day

Total daily dose (mg)

0.264

3.15

Patients with kidney disease

If you have moderate or severe kidney disease, your doctor will prescribe a lower dose. In this case, you will have to take the tablets only once or twice a day. If you have moderate kidney disease, the usual starting dose is 1 tablet MIRAPEXIN 0.088 mg twice a day. In severe kidney disease, the usual starting dose is just 1 tablet MIRAPEXIN 0.088 mg a day.

Restless Legs Syndrome

The dose is usually taken once a day, in the evening, 2–3 hours before bedtime.

During the first week, the usual dose is 1 tablet MIRAPEXIN 0.088 mg once a day (equivalent to 0.088 mg daily):

1st week

Number of tablets

1 tablet MIRAPEXIN 0.088 mg

Total daily dose (mg)

0.088

This will be increased every 4–7 days as directed by your doctor until your symptoms are controlled (maintenance dose).

2nd week

3rd week

4th week

Number of tablets

  • 1 tablet MIRAPEXIN 0.18 mg

OR

  • 2 tablets MIRAPEXIN 0.088 mg

  • 1 tablet MIRAPEXIN 0.35 mg

OR

  • 2 tablets MIRAPEXIN 0.18 mg

OR

  • 4 tablets MIRAPEXIN 0.088 mg

1 tablet MIRAPEXIN 0.35 mg and 1 tablet MIRAPEXIN 0.18 mg

OR

3 tablets MIRAPEXIN 0.18 mg

OR

6 tablets MIRAPEXIN 0.088 mg

Total daily dose (mg)

0.18

0.35

0.54

The daily dose should not exceed 6 tablets MIRAPEXIN 0.088 mg or a dose of 0.54 mg (0.75 mg pramipexole salt).

If you stop taking your tablets for more than a few days and want to restart the treatment, you must start again at the lowest dose. You can then build up the dose again, as you did the first time. Ask your doctor for advice.

Your doctor will review your treatment after 3 months to decide whether or not to continue the treatment.

Patients with kidney disease

If you have severe kidney disease, MIRAPEXIN may not be a suitable treatment for you.

If you take more MIRAPEXIN than you should

If you accidentally take too many tablets,

  • – Contact your doctor or nearest hospital casualty department immediately for advice.

  • – You may experience vomiting, restlessness, or any of the side effects as described in section 4

“Possible side effects”.

If you forget to take MIRAPEXIN

Do not worry. Simply leave out that dose completely and then take your next dose at the right time.

Do not try to make up for the missed dose.

If you stop taking MIRAPEXIN

Do not stop taking MIRAPEXIN without first talking to your doctor. If you have to stop taking this medicine, your doctor will reduce the dose gradually. This reduces the risk of worsening symptoms.

If you suffer from Parkinson’s disease you should not stop treatment with MIRAPEXIN abruptly. A sudden stop could cause you to develop a medical condition called neuroleptic malignant syndrome which may represent a major health risk. The symptoms include:

  • – akinesia (loss of muscle movement)

  • – rigid muscles

  • – fever

  • – unstable blood pressure

  • – tachycardia (increased heart rate)

  • – confusion

  • – depressed level of consciousness (e.g. coma)

If you stop or reduce MIRAPEXIN you may also develop a medical condition called dopamine agonist withdrawal syndrome. The symptoms include depression, apathy, anxiety, fatigue, sweating or pain. If you experience these symptoms you should contact your physician.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them. Evaluation of these side effects is based on the following frequencies:

Very common

may affect more than 1 in 10 people

Common

may affect up to 1 in 10 people

Uncommon

may affect up to 1 in 100 people

Rare

may affect up to 1 in 1,000 people

Very rare

may affect up to 1 in 10,000 people

Not known

Frequency cannot be estimated from the available data

If you suffer from Parkinson’s di­sease, you may experience the following side effects:

Very common:

  • – Dyskinesia (e.g. abnormal, uncontrolled movements of the limbs)

  • – Sleepiness

  • – Dizziness

  • – Nausea (sickness)

Common:

  • – Urge to behave in an unusual way

  • – Hallucinations (seeing, hearing or feeling things that are not there)

  • – Confusion

  • – Tiredness (fatigue)

  • – Sleeplessness (insomnia)

  • – Excess of fluid, usually in the legs (peripheral oedema)

  • – Headache

  • – Hypotension (low blood pressure)

  • – Abnormal dreams

  • – Constipation

  • – Visual impairment

  • – Vomiting (being sick)

  • – Weight loss including decreased appetite

Uncommon:

  • – Paranoia (e.g. excessive fear for one’s own well-being)

  • – Delusion

  • – Excessive daytime sleepiness and suddenly falling asleep

  • – Amnesia (memory disturbance)

  • – Hyperkinesia (increased movements and inability to keep still)

  • – Weight increase

  • – Allergic reactions (e.g. rash, itching, hypersensitivity)

  • – Fainting

  • – Cardiac failure (heart problems which can cause shortness of breath or ankle swelling)

  • – Inappropriate antidiuretic hormone secretion

  • – Restlessness

  • – Dyspnoea (difficulties to breathe)

  • – Hiccups

  • – Pneumonia (infection of the lungs)

  • – Inability to resist the impulse, drive or temptation to perform an action that could be harmful to

you or others, which may include:

  • – Strong impulse to gamble excessively despite serious personal or family consequences.

  • – Altered or increased sexual interest and behaviour of significant concern to you or to others, for example, an increased sexual drive.

  • – Uncontrollable excessive shopping or spending

  • – Binge eating (eating large amounts of food in a short time period) or compulsive eating (eating more food than normal and more than is needed to satisfy your hunger)

  • – Delirium (decreased awareness, confusion, loss of reality)

Rare:

  • – Mania (agitation, feeling elated or over-excited)

Not known:

  • – After stopping or reducing your MIRAPEXIN treatment: Depression, apathy, anxiety, fatigue, sweating or pain may occur (called dopamine agonist withdrawal syndrome or DAWS).

Tell your doctor if you experience any of these behaviours; he will discuss ways of managing or reducing the symptoms.

For the side effects marked with * a precise frequency estimation is not possible, since these side effects were not observed in clinical studies among 2,762 patients treated with pramipexole. The frequency category is probably not greater than “uncommon”.

If you suffer from Restless Legs Syndrome, you may experience the following side effects:

Very common:

  • – Nausea (sickness)

Common:

  • – Changes in sleep pattern, such as sleeplessness (insomnia) and sleepiness

  • – Tiredness (fatigue)

  • – Headache

  • – Abnormal dreams

  • – Constipation

Dizziness

Vomiting (being sick)

Uncommon:

  • – Urge to behave in an unusual way

  • – Cardiac failure (heart problems which can cause shortness of breath or ankle swelling)

  • – Inappropriate antidiuretic hormone secretion

  • – Dyskinesia (e.g. abnormal, uncontrolled movements of the limbs)

  • – Hyperkinesia (increased movements and inability to keep still)

  • – Paranoia (e.g. excessive fear for one’s own well-being)

  • – Delusion*

  • – Amnesia (memory disturbance)

  • – Hallucinations (seeing, hearing or feeling things that are not there)

  • – Confusion

  • – Excessive daytime sleepiness and suddenly falling asleep

  • – Weight increase

  • – Hypotension (low blood pressure)

  • – Excess of fluid, usually in the legs (peripheral oedema)

  • – Allergic reactions (e.g. rash, itching, hypersensitivity)

  • – Fainting

  • – Restlessness

  • – Visual impairment

  • – Weight loss including decreased appetite

  • – Dyspnoea (difficulties to breathe)

  • – Hiccups

  • – Pneumonia (infection of the lungs)

  • – Inability to resist the impulse, drive or temptation to perform an action that could be harmful to

you or others, which may include:

  • – Strong impulse to gamble excessively despite serious personal or family consequences.

  • – Altered or increased sexual interest and behaviour of significant concern to you or to others, for example, an increased sexual drive.

  • – Uncontrollable excessive shopping or spending*

  • – Binge eating (eating large amounts of food in a short time period) or compulsive eating (eating more food than normal and more than is needed to satisfy your hunger)

  • – Mania (agitation, feeling elated or over-excited)

  • – Delirium (decreased awareness, confusion, loss of reality)*

Not known:

  • – After stopping or reducing your MIRAPEXIN treatment: Depression, apathy, anxiety, fatigue, sweating or pain may occur (called dopamine agonist withdrawal syndrome or DAWS).

5. How to store MIRAPEXIN

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton after EXP. The expiry date refers to the last day of that month.

Do not store above 30°C.

Store in the original package to protect the tablets from light.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What MIRAPEXIN contains

The active substance is pramipexole.

Each tablet contains 0.088 mg, 0.18 mg, 0.35 mg, or 0.7 mg pramipexole as 0.125 mg, 0.25 mg, 0.5 mg, or 1 mg pramipexole dihydrochloride monohydrate, respectively.

The other ingredients are mannitol, maize starch, anhydrous colloidal silica, povidone K 25 and magnesium stearate.

What MIRAPEXIN looks like and contents of the pack

MIRAPEXIN 0.088 mg tablets are white, of round shape, flat, and without scoring.

MIRAPEXIN 0.18 mg tablets and MIRAPEXIN 0.35 mg tablets are white, of oval shape, and flat.

Tablets are scored on both sides and breakable in halves.

MIRAPEXIN 0.7 mg tablets are white, of round shape, and flat. Tablets are scored on both sides and breakable in halves.

All tablets have the Boehringer Ingelheim company symbol embossed on one side and the codes P6, P7, P8, or P9 on the other side, representing the tablet strengths 0.088 mg, 0.18 mg, 0.35 mg, and 0.7 mg, respectively.

All strengths of MIRAPEXIN are available in aluminium blister strips of 10 tablets per strip, in cartons containing 3 or 10 blister strips (30 or 100 tablets). Not all pack sizes may be marketed.

Marketing Authorisation Holder

Boehringer Ingelheim International GmbH

D-55216 Ingelheim am Rhein

Germany

Manufacturer

Boehringer Ingelheim Pharma GmbH & Co. KG

D-55216 Ingelheim am Rhein

Germany

Boehringer Ingelheim France 100–104 avenue de France 75013 Paris

France

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

België/Belgiqu­e/Belgien

SCS Boehringer Ingelheim Comm.V

Tél/Tel: +32 2 773 33 11


Etnrapua

EtopuHrep Hwre.ixaHM PUB PmoX u Ko. Kr -k.toh Ebnrapua

Ten: +359 2 958 79 98

Česká republika

Boehringer Ingelheim spol. s r.o.

Tel: +420 234 655 111


Lietuva

Boehringer Ingelheim RCV GmbH & Co KG

Lietuvos filialas

Tel: +370 5 2595942

Luxembourg/Lu­xemburg

SCS Boehringer Ingelheim Comm.V

Tel/Tel: +32 2 773 33 11


Danmark

Boehringer Ingelheim Danmark A/S

Tlf: +45 39 15 88 88

Deutschland

BIOTHERAX biochemisch-pharmazeutische

Gesellschaft mbH

Tel: +49 (0) 800 77 90 900

Eesti

Boehringer Ingelheim RCV GmbH & Co KG

Eesti filiaal

Tel: +372 612 8000

EXXáSa

Boehringer Ingelheim Ellas A.E.

Tql: +30 2 10 89 06 300

España

Boehringer Ingelheim España, S.A.

Tel: +34 93 404 51 00

France

Boehringer Ingelheim France S.A.S.

Tél: +33 3 26 50 45 33

Hrvatska

Boehringer Ingelheim Zagreb d.o.o.

Tel: +385 1 2444 600


Ireland

Boehringer Ingelheim Ireland Ltd.

Tel: +353 1 295 9620


Magyarorszag

Boehringer Ingelheim RCV GmbH & Co KG

Magyarorszagi Fioktelepe

Tel: +36 1 299 89 00

Malta

Boehringer Ingelheim Ireland Ltd.

Tel: +353 1 295 9620

Nederland

Boehringer Ingelheim b.v.

Tel: +31 (0) 800 22 55 889

Norge

Boehringer Ingelheim Norway KS

Tlf: +47 66 76 13 00

Österreich

Boehringer Ingelheim RCV GmbH & Co KG

Tel: +43 1 80 105–7870

Polska

Boehringer Ingelheim Sp.zo.o.

Tel: +48 22 699 0 699

Portugal

Boehringer Ingelheim Portugal, Lda.

Tel: +351 21 313 53 00

Romania

Boehringer Ingelheim RCV GmbH & Co KG

Viena – Sucursala Bucuresti

Tel: +40 21 302 28 00

Slovenija

Boehringer Ingelheim RCV GmbH & Co KG

Podruznica Ljubljana

Tel: +386 1 586 40 00


Ísland

Vistor hf.

Sími: +354 535 7000


Slovenská republika

Boehringer Ingelheim RCV GmbH & Co KG organizačná zložka

Tel: +421 2 5810 1211


Italia

Boehringer Ingelheim Italia S.p.A.

Tel: +39 02 5355 1

Kvnpog

Boehringer Ingelheim Ellas A.E.

Tql: +30 2 10 89 06 300

Latvija

Boehringer Ingelheim RCV GmbH & Co KG

Latvijas filiäle

Tel: +371 67 240 011


Suomi/Finland

Boehringer Ingelheim Finland Ky

Puh/Tel: +358 10 3102 800

Sverige

Boehringer Ingelheim AB

Tel: +46 8 721 21 00

United Kingdom (Northern Ireland)

Boehringer Ingelheim Ireland Ltd.

Tel: +353 1 295 9620


This leaflet was last revised in {MM/YYYY}.

Detailed information on this medicine is available on the European Medicines Agency web site:.